Conclusions
hepatic steatosis, fibrosis
RECRUITMENT, HEPATIC STEATOSIS, FIBROSIS
This feasibility study provides preliminary evidence of maraviroc safety amongst people with HIV-NAFLD, and acceptable recruitment, retention, and adherence rates. These data support a definitive randomised-controlled trial assessing maraviroc impact on hepatic steatosis and fibrosis.